

Diagnostic and Prognostic Value of Global Longitudinal Strain in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

1 **Yujiao Shi¹, Wang Qing¹, Chunqiu Liu¹, Xiong Shuang¹, Chenguang Yang¹,**

2 **Wenbo Qiao¹, Guoju Dong^{1,2*}, Jiangang Liu^{2*}**

3

4 ¹Department of Cardiovascular Internal Medicine, Xiyuan Hospital, Chinese Academy of
5 Traditional Chinese Medicine, Beijing, China

6 ²National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital,
7 Chinese Academy of Traditional Chinese Medicine, Beijing, China

8

9 * Corresponding Author

10 E-mail: Guoju Dong. e-mail: 13691393589@163.com (GD); liujiangang2002@sina.com
11 (JL)

12

13

14

15

16

17

18

19

20

21

22

23

24

25 **Abstract**

26 **Objective:** Heart failure with preserved ejection fraction (HFpEF), an increasing public
27 health concern, is increasing in prevalence and is associated with an elevated risk of
28 hospitalization and mortality. Currently, data on the clinical application value of left
29 ventricular global longitudinal strain (LV GLS) in HFpEF are contradictory. Therefore,
30 we performed the following meta-analysis to appraise the diagnostic and prognostic value
31 of LV GLS in HFpEF.

32 **Methods:** PubMed, Medline, Scopus, and Web of Science were retrieved exhaustively
33 from their inception until December 20, 2022, to obtain literature assessing the diagnostic
34 and prognostic value of LV GLS in HFpEF.

35 **Results:** Forty-one studies (including 14,543 patients) published from 2008 to 2022 were
36 included. The results of the meta-analysis were as follows: First, the LV GLS values in
37 HFpEF patients were significantly lower than in healthy individuals (SMD:1.21; 95% CI
38 (0.94, 1.47), $p < 0.00001$, $I^2 = 85\%$; $P < 0.00001$), but substantially higher than in HREEF
39 patients (SMD: -2.03; 95% CI (-2.23, -1.72), $p < 0.00001$, $I^2 = 92\%$; $P < 0.00001$). Second,
40 the pooled diagnostic parameters of LV GLS for HFpEF were as follows: sensitivity,
41 0.77 (95% CI: 0.71–0.82); specificity, 0.66 (95% CI: 0.58–0.74); DOR, 7.53 (95% CI:
42 3.19–17.74); AUC for the SROC, 0.81 (95% CI: 0.79–0.87). Finally, the low LV GLS
43 values were correlated with a higher risk of all-cause death (HR: 1.12; 95% CI: 1.01-
44 1.25; $p = 0.000$, $I^2 = 84\%$; $P = 0.031$) in HFpEF patients.

45 **Conclusions:** LV GLS is impaired in HFpEF patients despite a normal left ventricular
46 ejection fraction, indicating the existence of mild LV contractile dysfunction. Moreover,
47 LV GLS might be an auxiliary indicator for diagnosing HFpEF and predicting all-cause

48 death in HFpEF patients.

49 **Keywords:** Global longitudinal strain; Heart failure with preserved ejection fraction;

50 Diagnosis; Prognosis; Meta-analysis

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71 1 Introduction

72 Heart failure (HF) with preserved ejection fraction (HFpEF), a complex and
73 heterogeneous ailment, is a multi-organ disorder caused by an aging populace and
74 comorbidities such as obesity, hypertension, diabetes, and chronic renal insufficiency[1].
75 HFpEF, comprising approximately half of the population of HF, is increasing in
76 prevalence and is associated with an elevated risk of hospitalization and mortality[2,3].
77 Nevertheless, the clinical manifestations of HFpEF are atypical, and the pathogenic
78 mechanism remains poorly understood, limiting clinical diagnosis and therapeutic
79 options[4,5]. Accordingly, early and accurate diagnosis of HFpEF and determination of
80 prognosis can contribute to implementing appropriate interventions to slow or halt
81 disease progression and improve long-term consequences.

82 Despite the fact that patients with HFpEF have a left ventricular (LV) ejection
83 fraction (LVEF) of greater than or equal to 50%, cardiac contractile performance may
84 still be damaged, especially in individuals with severe concentric cardiac hypertrophy or
85 a small LV cavity[6]. LVEF, a measure of overall cardiac systolic function derived from
86 two-dimensional echocardiographic images, may be limited by altered cardiac geometry,
87 boundary tracking difficulties, and other factors[7,8]. Compared with LVEF
88 measurement, myocardial strain, which represents the percentage deformation of the
89 myocardium in three directions (longitudinal, circumferential, and radial) during the
90 cardiac cycle, is an emerging metric allowing more precise quantification of global and
91 regional myocardial contractile function[9]. LV global longitudinal strain (LV GLS),
92 which can be measured by speckle-tracking echocardiography (STE) or feature-tracking
93 cardiovascular magnetic resonance (FT-CMR), is a commonly used myocardial strain

94 parameter in cardiovascular diseases[10]. In recent years, multiple clinical trials have
95 analyzed the diagnostic or prognostic significance of LV GLS in HFpEF, but they
96 provided inconsistent results. In this situation, we implemented a meta-analysis to
97 estimate the diagnostic and prognostic value of LV GLS in HFpEF.

98

99 **2 Materials and methods**

100 **2.1 Literature Search Strategy**

101 This systematic review and meta-analysis was performed depending on the principles
102 of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020
103 statement (PRISMA)[11]. Two investigators (Shi and Wang) systematically performed
104 documentary searches in four electronic databases (PubMed, Medline, Scopus, and Web
105 of Science). English-language literature published from the inception of each database
106 until December 20, 2022, was searched. Terms related to "Heart Failure, Diastolic",
107 "Heart Failure with Preserved Ejection Fraction", "Heart Failure with Normal Ejection
108 Fraction", "Diastolic Dysfunction", " Preserved Ejection Fraction", "Global Longitudinal
109 Strain", and "GLS" were utilized following the rules of each database. For PubMed, the
110 following search was performed: (((((Heart Failure, Diastolic[MeSH Terms]) OR (Heart
111 Failure with Preserved Ejection Fraction[Title/Abstract])) OR (Heart Failure with Normal
112 Ejection Fraction[Title/Abstract])) OR (Diastolic Dysfunction[Title/Abstract])) OR
113 (Preserved Ejection Fraction[Title/Abstract])) AND ((Global Longitudinal
114 Strain[Title/Abstract]) OR (GLS[Title/Abstract]))

115 **2.2 Literature Inclusion and Exclusion Criteria**

116 The inclusion criteria for this study were as follows: (i) diagnostic criteria: Fulfilment
117 of diagnostic criteria for HF, patients with HFpEF had an LVEF \geq 45%, while HFrEF
118 patients had an LVEF \leq 40%[12,13]; (ii) study design: observational studies like case-
119 control studies, prospective and retrospective cohort studies; (ii) endpoints: difference in
120 LV GLS values between HFpEF patients and control groups (health controls or HFrEF
121 patients), as well as the connection between LV GLS and diagnosis or adverse endpoints
122 of HFpEF. The exclusion criteria for this study were as follows: (i) irrelevant or
123 duplicated studies; (ii) the papers were case reports, reviews, letters, commentaries,
124 editorials, or non-human studies; and (iii) the articles lacked full text or sufficient crude
125 data.

126 **2.3 Literature Quality Evaluation and Data Extraction**

127 The quality estimation of the enrolled studies was evaluated by two independent
128 reviewers (Xiong and Liu) using the Newcastle–Ottawa Quality Assessment Scale (NOS)
129 system, a "star-based" grading system comprised of three parts (selection, comparability,
130 and outcomes). A total NOS score ranged from 0 to 9, and studies achieving a score of 6
131 or above were considered high quality (Supplementary Table 1).

132 The required data from the included research was extracted and tabulated in
133 specifically constructed Microsoft Excel spreadsheets for analysis. The extracted contents
134 were as follows: (i) publication details: last name of the first author, year of publication,
135 and the country setting; (ii) demographic characteristics: sample size, proportions of
136 males, and mean age; (iii) study details: study design, LV GLS measurement method,
137 data available to calculate the standardized mean difference (SMD) of LV GLS values
138 between HFpEF patients and control groups (sample size, mean of LV GLS values and

139 standard deviation), data related to diagnostic meta-analysis (LV GLS cut-off, area under
140 the curve (AUC), sensitivity (SEN), specificity (SPE), true positive (TP), false positive
141 (FP), false negative (FN), true negative (TN)), and data associated with prognostic meta-
142 analysis (variables adjusted, follow-up duration, endpoints (HF hospitalization,
143 cardiovascular (CV) hospitalization, CV death, and All-cause death), hazard ratios (HRs)
144 and 95% confidence intervals (CIs)); and (iv) NOS quality scores. Two independent
145 researchers (Yang and Qiao) conducted data extraction, and disagreements were resolved
146 by mutual coordination or third-party adjudication (Dong and Liu).

147 **2.4 Statistical Analysis**

148 Meta-Disc (Version 14.0) was used to analyze the diagnostic value of LV GLS in
149 HFpEF. The pooled SEN, SPE, positive likelihood ratio (PLR), negative likelihood ratio
150 (NLR), diagnostic odds ratio (DOR), and AUC for the summary receiver operating
151 characteristic curves (SROC) were used to characterize the diagnostic performance.
152 Review Manager (Version 5.4) was used to analyze the difference in LV GLS values
153 between HFpEF patients and control groups. SMD and 95% CIs expressed the pooled
154 effect sizes. STATA (Version 16.0) was used to assess the association between LV GLS
155 and adverse outcomes of HFpEF. HRs and 95% CIs represented the pooled effect sizes.
156 The heterogeneity among the included studies was appraised by the Cochran Q statistics
157 (chi-square test) and quantified with the I² statistic. The fixed-effect model was
158 employed when the Q test (I²<50%, p>0.05) revealed no significant heterogeneity across
159 studies. When the Q test (I²≥50% or p<0.05) found prominent heterogeneity among
160 studies, the random-effect model was utilized, followed by a Galbraith plot to explore the
161 source of heterogeneity. Publication bias was evaluated using Deeks' funnel plot, Funnel

162 plot, and Egger's test. Sensitivity analysis was employed to assess the impact of single
163 research on the overall estimate by omitting one study each time. $P < 0.05$ was considered
164 to be statistically significant.

165

166 **3 Results**

167 **3.1 Literature Search Results**

168 A flowchart of the database search and text screening procedure is demonstrated in
169 Fig 1. 2,492 publications were retrieved through database searching, consisting of 372
170 from PubMed, 624 from Medline, 559 from Scopus, and 937 from Web of Science. After
171 excluding 874 duplicates, we screened the titles and abstracts of 1,618 papers. 1,524
172 articles were removed following the inclusion and exclusion criteria. Finally, among the
173 remaining 94 studies, two independent researchers (Shi and Wang) read the full text and
174 excluded 53 records due to repetitive research, irrelevant results, and insufficient data.
175 Overall, 41 articles in total were enrolled in the meta-analysis.

176 **3.2 Characteristics of Included Studies**

177 Forty-one studies [14-53] published from 2008 to 2022 were investigated, including
178 27 case-control studies, 12 prospective cohort studies, and 2 retrospective cohort studies.
179 Table 1 shows the baseline features of the selected research. A total of 14,543 patients
180 (10,193 HFpEF patients, 6,931 males, mean age of 67.66 years) were involved. Thirty-
181 two studies detected LV GLS using STE, and the other 9 utilizing FT-CMR. Thirty-eight
182 studies reported mean LV GLS values in HFpEF patients (-8.2% - -20.8%), whereas the

183 remaining 3 informed the median values (-15.3% - -20%). Concerning endpoint events,
184 27 studies evaluated the differences in LV GLS values between HFpEF patients and
185 healthy controls (21 research) or HFrEF patients (16 research), and 26 studies assessed
186 the diagnostic (6 trials) and prognostic (18 trials) significance of LV GLS in HFpEF. The
187 NOS scores of included research varied from 6 to 9, indicating that the methodological
188 quality was generally reliable (**S1 Appendix**).

189 **3.3 Differences in LV GLS Values Between HFpEF Patients and Control Groups**

190 Twenty-one studies[14–34] explored the differences in LV GLS values between
191 HFpEF patients (n=1431) and healthy controls (n=864), with a mean LV GLS of -
192 16.07%±3.32% vs. -19.54%± 2.57% (Fig 2A). Moreover, 16 studies[14–18,21,26,30,33–
193 40] examined discrepancies in LV GLS values between HFpEF patients (n=2,234) and
194 HFrEF patients (n=3,355), with an average LV GLS of -16.42%±3.56% vs. -9.3%±3.48%
195 (Fig 2B). Meta-analysis using a random-effect model revealed that the LV GLS values in
196 HFpEF patients were significantly lower than in healthy individuals (SMD:1.21; 95% CI
197 (0.94, 1.47), p<0.00001, I²=85%; P<0.00001) (Fig 2C), but substantially higher than in
198 HErEF patients (SMD: -2.03; 95% CI (-2.23, -1.72), p<0.00001, I²=92%; P<0.00001)
199 (Fig 2D). According to the Galbraith radial plots, the research by (Fang et al., Wang et
200 al., Sanchis et al.) and (Maffei et al., Carluccio et al., and Yip et al.) were sources of
201 heterogeneity for the above two comparison groups, respectively (S2 Appendix. 1A,
202 2A).

203 The associated Funnel plots were asymmetrical (S2 Appendix. 1B, 2B) and the p-values
204 of Egger's test were 0.2 and 0.41 (S2 Appendix. 1C, 2C), indicating a potential
205 publication bias among included studies. The sensitivity analyses removing one research

206 each time indicated that none of the individual trials substantially impacted the pooled
207 estimates (S2 Appendix. 1D, 2D). Overall, the results of this study were relatively
208 constant.

209 **3.4 Diagnostic Value of LVGLS in HFpEF**

210 Six studies[20,23,27,31–33] estimated the diagnostic usefulness of LV GLS values in
211 HFpEF compared with healthy controls, with LV GLS cut-off values ranging from -16%
212 to -24.1 and AUC from 0.68 to 0.98 (Table 2). Five trails provided complete data for
213 diagnostic meta-analysis (SEN, SPN, TP, FP, FN, and TN). The SROC curve revealed no
214 typical "shoulder-arm" pattern, while the Spearman correlation coefficient between the
215 logarithm of sensitivity and the logarithm of (1-specificity) was -0.1, $P=0.873$, suggesting
216 no threshold effect in the meta-analysis. Summary assessments of the diagnostic
217 performance of LV GLS in HFpEF were as follows: SEN was 0.77 (95% CI: 0.71–0.82)
218 (Fig 3A); SPE was 0.66 (95% CI: 0.58–0.74) (Fig 3B); PLR was 2.17 (95% CI: 1.36–
219 3.47) (Fig 3C); NLR was 0.35 (95% CI: 0.21–0.59) (Fig 3D); DOR was 7.53 (95% CI:
220 3.19–17.74) (Fig 3E); AUC for the SROC was 0.81 (95% CI: 0.79–0.87) (Fig 3F). The p-
221 value of Deeks' test (0.18) was greater than 0.05, suggesting no significant publication
222 bias. (S2 Appendix. 3).

223 **3.5 Prognostic Value of LV GLS in HFpEF Patients**

224 Eighteen studies[6,28,37,40–53] examined the connection between LV GLS values as
225 a continuous variable and adverse outcomes in HFpEF patients. The duration of follow-
226 up varied from 4 to 144 months. In 9 studies, variables such as age, sex, race, history of
227 CV disease, medication history, laboratory tests, and others that might affect the

228 association between LV GLS and research outcomes were adjusted (Table 3). Meta-
229 analyzes with random-effects models showed that the low LV GLS values in HFpEF
230 patients were associated with a higher risk of all-cause death (HR: 1.12; 95% CI: 1.01-
231 1.25; $p=0.000$, $I^2=84\%$; $P = 0.031$)[29,42,44,47,49,51] (Fig 4A), but not with the
232 composite outcomes (all-cause death and HF hospitalization (HR: 1.03; 95% CI: 0.95-
233 1.11; $p=0.000$, $I^2= 83\%$; $P = 0.51$)[29,45–48,51,52] (Fig 4B) or CV death and HF
234 hospitalization (HR: 1.04; 95% CI: 0.94-1.14; $p=0.000$, $I^2= 81\%$; $P = 0.49$))
235 [6,28,37,41,43] (Fig 4C)). Additionally, three studies by Xu et al., Freed et al., and
236 Kosmala et al. reported no association between low LV GLS values in HFpEF patients
237 and the composite outcome of all-cause death and CV hospitalization [40,50,53]. The
238 result for all-cause death showed substantial heterogeneity. The Galbraith radial plot
239 suggested that the studies by Romano2020 et al. and Buggy2017 et al. may be the
240 source of heterogeneity (S2 Appendix. 4A). the associated Funnel plot was asymmetric
241 (S2 Appendix. 4B) and the p-value of Egger's test was 0.67 (S2 Appendix. 4C),
242 suggesting a possible publication bias across included studies. The sensitivity analysis
243 indicated that none of the studies significantly affected the pooled estimates (S2
244 Appendix. 4D).

245

246 **4 Discussion**

247 Current European Society of Cardiology guidelines graded HF based on LVEF into
248 reduced (LVEF \leq 40%), mildly reduced (LVEF 41-49%), and preserved (LVEF \geq 50%)
249 three subtypes[13]. HFpEF, which accounts for about half of all HF, is evolving as an
250 increasingly severe public health concern[2]. Presently, HFpEF is diagnosed depending

251 on representative symptoms and/or signs of HF (breathlessness, fatigue, edema, and
252 others), an LVEF of more than 50%, objective evidence of cardiac structural or
253 functional abnormalities, and a growing level of BNP or NT pro-BNP[5]. However, most
254 sufferers lack specific clinical manifestations in the initial stages and are usually not
255 detected until the impairment of cardiac structure and function develops [54]. It is
256 essential to explore effective metrics for identifying high-risk individuals, early
257 diagnosis, prognosis assessment, and treatment monitoring.

258 During cardiac systole, the obliquely and oppositely oriented subendocardial and
259 epicardial myofibers produce apical counter-clockwise torsion and basal clockwise
260 torsion, causing the LV to shorten in the longitudinal and circumferential planes while
261 thickening in the radial plane[55]. Cardiac strain assesses the change in length of the
262 myocardium in three planes (longitudinal and circumferential (expressed by a negative
263 value), radial (represented by a positive value) relative to the initial length during the
264 cardiac cycle. It can be calculated using the following formula: strain (epsilon) = $L - L_0 / L_0$ (where L_0 is the baseline length of the myocardium, and L is the length after
265 deformation)[7]. LV GLS, a sensitive and objective diagnostic indicator in cardiac strain
266 imaging, can detect LV mild contractile dysfunction before changes in LVEF[8]. It is
267 currently used as an auxiliary parameter for diagnosis and prognostic assessment in
268 cardio-oncology[56] and is being expanded to other fields such as cardiac
269 amyloidosis[57], cardiomyopathies[58], valvular heart diseases[59], pulmonary
270 hypertension[60], and HF[58]. Although numerous studies have confirmed the presence
271 of abnormal LV GLS in HFpEF patients and the Heart Failure Association consensus has
272 unanimously recommended impaired V GLS as an ancillary criterion for the diagnosis of
273

274 HFpEF[54], there is controversy about whether LV GLS has independent diagnostic and
275 prognostic value for HFpEF. We consequently performed this meta-analysis to assess the
276 diagnostic and prognostic value of LV GLS in HFpEF.

277 The results of the current meta-analysis illustrated a significant link between LV GLS
278 and the diagnosis and prognosis of HFpEF. First, the LV GLS values in HFpEF patients
279 were significantly lower than in healthy individuals, but substantially higher than in
280 HErEF patients, confirming the presence of mild LV systolic dysfunction in HFpEF
281 patients. The longitudinal systolic function of LV is determined by the endocardium,
282 which is highly susceptible to the detrimental impacts of ischemia or hypertrophy[61,62].
283 Multiple comorbidities in HFpEF patients may promote microvascular malfunction and
284 muscle fibrosis[63], reducing LV longitudinal systolic function and ultimately leading to
285 LV GLS impairment. Second, LV GLS has excellent auxiliary diagnostic value for
286 HFpEF, with with an AUC of 0.81 (95% CI: 0.79–0.87). Finally, the low LV GLS values
287 in HFpEF patients were correlated with a higher risk of all-cause death, indicating that
288 LV GLS is a powerful independent predictor of all-cause mortality in HFpEF patients.

289 This meta-analysis involved a relatively comprehensive literature search, and the
290 included studies were of excellent quality according to the NOS score. Nonetheless, some
291 limitations must be considered: First, the heterogeneity of the included studies was high,
292 with probable causes including the detection method of LV GLS, the diagnostic criteria
293 of HF, and the study design. Second, in the diagnostic meta-analysis, the diagnostic cut-
294 off values of LV GLS were not consistent, which might be related to factors like the
295 detection technique. Third, in the prognostic meta-analysis, the follow-up periods were
296 inconsistent, and the number of studies in which effect sizes could be combined for the

297 same endpoint was low, limiting the ability to draw significant conclusions. As a result,
298 our meta-analysis is exploratory, and further high-quality original research is needed to
299 support the findings of this study.

300

301 **5 Conclusion**

302 LV GLS is impaired in HFpEF patients despite a normal left ventricular ejection
303 fraction, indicating the existence of mild LV contractile dysfunction. Moreover, LV GLS
304 might be an auxiliary indicator for diagnosing HFpEF and predicting all-cause death in
305 HFpEF patients.

306

307 **6 Supporting information**

308 **S1 Appendix. NOS score of the included studies (PDF)**

309 **S2 Appendix. Heterogeneity, publication bias, and sensitivity analysis of relevant**
310 **meta-analyses (PDF)**

311 **S3 Appendix. PRISMA checklist (PDF)**

312

313 **7 Acknowledgments**

314 The authors would like to express their gratitude to Professor W. Szymański for his
315 valuable help in the process of retrieving relevant literature.

316

317

318 **8 Author Contributions**

319 **Conceptualization:** Yujiao Shi, Guoju Dong, Jiangang Liu

320 **Data curation:** Yujiao Shi, Wang Qing

321 **Formal analysis:** Wang Qing, Chunqiu Liu, Xiong Shuang

322 **Investigation:** Chenguang Yang, Wenbo Qiao

323 **Methodology:** Yujiao Shi, Guoju Dong, Jiangang Liu

324 **Project administration:** Wang Qing, Chunqiu Liu, Xiong Shuang

325 **Supervision:** Guoju Dong, Jiangang Liu

326 **Visualization:** Yujiao Shi, Chunqiu Liu

327 **Writing – original draft:** Guoju Dong, Jiangang Liu

328 **Writing – review & editing:** Yujiao Shi, Guoju Dong, Jiangang Liu

329

330 **9 Data availability statement**

331 All relevant data are within the paper.

332

333 **10 Funding**

334 This study was supported by grants from the National Natural Science Foundation of

335 China (8207153216) and the Major Innovation Project of the China Academy of

336 Traditional Chinese Medicine (CI2021A00903).

337

338

339

340 Reference

- 341 1. Borlaug BA. Evaluation and management of heart failure with preserved ejection
342 fraction. *Nature Reviews Cardiology* (2020) 17:559–73. doi: 10.1038/s41569-
343 020-0363-2
- 344 2. Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R,
345 Chirinos JA, Collins S, Deo RC, Gladwin MT, et al. Research Priorities for Heart
346 Failure With Preserved Ejection Fraction. *Circulation* (2020) 141:1001–26. doi:
347 10.1161/circulationaha.119.041886
- 348 3. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with
349 preserved ejection fraction. *Nature Reviews Cardiology* (2017) 14:591–602. doi:
350 10.1038/nrcardio.2017.65
- 351 4. Omote K, Verbrugge FH, Borlaug BA. Heart Failure with Preserved Ejection
352 Fraction: Mechanisms and Treatment Strategies. *Annual Review of Medicine*
353 (2022) 73:321–37. doi: 10.1146/annurev-med-042220-022745
- 354 5. Nagueh SF. Heart Failure with Preserved Ejection Fraction: Insights into
355 Diagnosis and Pathophysiology. *Cardiovascular Research* (2021) 117:999–1014.
356 doi: 10.1093/cvr/cvaa228
- 357 6. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer
358 MA, Solomon SD. Prognostic Importance of Impaired Systolic Function in Heart
359 Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
360 *Circulation* (2015) 132:402–14. doi: 10.1161/CIRCULATIONAHA.115.015884
- 361 7. Potter E, Marwick TH. Assessment of Left Ventricular Function by
362 Echocardiography. *JACC: Cardiovascular Imaging* (2018) 11:260–74. doi:
363 10.1016/j.jcmg.2017.11.017
- 364 8. Nauta JF, Jin X, Hummel YM, Voors AA. Markers of left ventricular systolic
365 dysfunction when left ventricular ejection fraction is normal. *European Journal*
366 *of Heart Failure* (2018) 20:1636–8. doi: 10.1002/ejhf.1326
- 367 9. Halliday BP, Senior R, Pennell DJ. Assessing left ventricular systolic function:
368 from ejection fraction to strain analysis. *European Heart Journal* (2021) 42:789–
369 97. doi: 10.1093/eurheartj/ehaa587
- 370 10. Amzulescu MS, De Craene M, Langet H, Pasquet A, Vancraeynest D, Pouleur
371 AC, Vanoverschelde JL, Gerber BL. Myocardial strain imaging: review of
372 general principles, validation, and sources of discrepancies. *European Heart*
373 *Journal - Cardiovascular Imaging* (2019) 20:605–19. doi: 10.1093/ehjci/jez041
- 374 11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,
375 Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020
376 statement: an Updated Guideline for Reporting Systematic Reviews. *British*
377 *Medical Journal* (2021) 372:n71. doi: 10.1136/bmj.n71
- 378 12. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez
379 F, Packer M, Pfeffer MA, Pieske B, et al. Angiotensin–Neprilysin Inhibition in
380 Heart Failure with Preserved Ejection Fraction. *New England Journal of*
381 *Medicine* (2019) 381:1609–20. doi: 10.1056/nejmoa1908655
- 382 13. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri
383 H, Butler J, Čelutkienė J, Chioncel O, et al. 2021 ESC Guidelines for the
384 Diagnosis and Treatment of Acute and Chronic Heart Failure. *European Heart*
385 *Journal* (2021) 42:3599–726. doi: 10.1093/eurheartj/ehab368

- 386 14. Bekfani T, Hamadanchi A, Ijuin S, Bekhite M, Nisser J, Derlien S, Westphal J,
387 Bogoviku J, Morris DA, Fudim M, et al. Relation of left atrial function with
388 exercise capacity and muscle endurance in patients with heart failure. *ESC Heart*
389 *Failure* (2021) 8:4528–38. doi: 10.1002/ehf2.13656
- 390 15. Blum M, Hashemi D, Motzkus LA, Neye M, Dordevic A, Zieschang V, Zamani
391 SM, Lapinskas T, Runte K, Kelm M, et al. Variability of Myocardial Strain
392 During Isometric Exercise in Subjects With and Without Heart Failure. *Frontiers*
393 *in Cardiovascular Medicine* (2020) 7:111. doi: 10.3389/fcvm.2020.00111
- 394 16. Bosch L, Lam CSP, Gong L, Chan SP, Sim D, Yeo D, Jaufeerally F, Leong
395 KTG, Ong HY, Ng TP, et al. Right ventricular dysfunction in left-sided heart
396 failure with preserved versus reduced ejection fraction. *European Journal of*
397 *Heart Failure* (2017) 19:1664–71. doi: 10.1002/ejhf.873
- 398 17. Bshiebish HAH, Al-Musawi AH, Khudeir SA. Role of global longitudinal strain
399 in assessment of left ventricular systolic function in patients with heart failure
400 with preserved ejection fraction. *Journal of the Saudi Heart Association* (2019)
401 31:100–5. doi: 10.1016/j.jsha.2018.12.002
- 402 18. Carluccio E, Biagioli P, Alunni G, Murrone A, Leonelli V, Pantano P, Biscottini
403 E, Paulus WJ, Ambrosio G. Advantages of deformation indices over systolic
404 velocities in assessment of longitudinal systolic function in patients with heart
405 failure and normal ejection fraction. *European Journal of Heart Failure* (2011)
406 13:292-02. doi: 10.1093/eurjhf/hfq203
- 407 19. Carluccio E, Biagioli P, Zuchi C, Bardelli G, Murrone A, Lauciello R, D’Addario
408 S, Mengoni A, Alunni G, Ambrosio G. Fibrosis assessment by integrated
409 backscatter and its relationship with longitudinal deformation and diastolic
410 function in heart failure with preserved ejection fraction. *The International*
411 *Journal of Cardiovascular Imaging* (2016) 32:1071–80. doi: 10.1007/s10554-
412 016-0881-5
- 413 20. Fang S, Zhang Z, Wang Y, Jiang F, Yang K, He F, Zhang C. Predictive value of
414 left ventricular myocardial strain by four-dimensional speckle tracking
415 echocardiography combined with red cell distribution width in heart failure with
416 preserved ejection fraction. *Echocardiography* (2019) 36:1074–83. doi:
417 10.1111/echo.14373
- 418 21. Hashemi D, Motzkus L, Blum M, Kraft R, Tanacli R, Tahirovic E, Doebelin P,
419 Zieschang V, Zamani SM, Kelm M, et al. Myocardial deformation assessed
420 among heart failure entities by cardiovascular magnetic resonance imaging. *ESC*
421 *Heart Failure* (2021) 8:890–7. doi: 10.1002/ehf2.13193
- 422 22. Ito H, Ishida M, Makino W, Goto Y, Ichikawa Y, Kitagawa K, Omori T, Dohi K,
423 Ito M, Sakuma H. Cardiovascular magnetic resonance feature tracking for
424 characterization of patients with heart failure with preserved ejection fraction:
425 correlation of global longitudinal strain with invasive diastolic functional indices.
426 *Journal of Cardiovascular Magnetic Resonance* (2020) 22:42. doi:
427 10.1186/s12968-020-00636-w
- 428 23. Kim HY, Park S-J, Lee S-C, Chang SY, Kim E-K, Chang S-A, Choi J-O, Park
429 SW, Kim S-M, Choe YH, et al. Comparison of global and regional myocardial
430 strains in patients with heart failure with a preserved ejection fraction vs
431 hypertension vs age-matched control. *Cardiovascular Ultrasound* (2020) 18:44.

- 432 doi: 10.1186/s12947-020-00223-0
433
434 24. Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile
435 MR, Voors AA, Lefkowitz MP, Packer M, et al. Impaired Systolic Function by
436 Strain Imaging in Heart Failure With Preserved Ejection Fraction. *Journal of the*
437 *American College of Cardiology* (2014) 63:447–56. doi:
438 10.1016/j.jacc.2013.09.052
439 25. Löffler AI, Pan JA, Balfour PC, Shaw PW, Yang Y, Nasir M, Auger DA, Epstein
440 FH, Kramer CM, Gan L-M, et al. Frequency of Coronary Microvascular
441 Dysfunction and Diffuse Myocardial Fibrosis (Measured by Cardiovascular
442 Magnetic Resonance) in Patients With Heart Failure and Preserved Left
443 Ventricular Ejection Fraction. *The American Journal of Cardiology* (2019)
444 124:1584–9. doi: 10.1016/j.amjcard.2019.08.011
445 26. Luo X-X, Fang F, Lee AP-W, Sun J-P, Li S, Zhang Z-H, Sanderson JE, Kwong
446 JSW, Zhang Q, Wang J, et al. What can three-dimensional speckle-tracking
447 echocardiography contribute to evaluate global left ventricular systolic
448 performance in patients with heart failure? *International Journal of Cardiology*
449 (2014) 172:132–7. doi: 10.1016/j.ijcard.2013.12.314
450 27. Mordi IR, Singh S, Rudd A, Srinivasan J, Frenneaux M, Tzemos N, Dawson DK.
451 Comprehensive Echocardiographic and Cardiac Magnetic Resonance Evaluation
452 Differentiates Among Heart Failure With Preserved Ejection Fraction Patients,
453 Hypertensive Patients, and Healthy Control Subjects. *JACC: Cardiovascular*
454 *Imaging* (2018) 11:577–85. doi: 10.1016/j.jcmg.2017.05.022
455 28. Pellicori P, Kallvikbacka-Bennett A, Khaleva O, Carubelli V, Costanzo P,
456 Castiello T, Wong K, Zhang J, Cleland JGF, Clark AL. Global longitudinal strain
457 in patients with suspected heart failure and a normal ejection fraction: does it
458 improve diagnosis and risk stratification? *The International Journal of*
459 *Cardiovascular Imaging* (2013) 30:69–79. doi: 10.1007/s10554-013-0310-y
460 29. Roy C, Lejeune S, Slimani A, Meester C, Ahn AS SA, Rousseau MF, Mihaela A,
461 Ginion A, Ferracin B, Pasquet A, et al. Fibroblast growth factor 23: a biomarker
462 of fibrosis and prognosis in heart failure with preserved ejection fraction. *ESC*
463 *Heart Failure* (2020) 7:2494–507. doi: 10.1002/ehf2.12816
464 30. Sanchis L, Gabrielli L, Andrea R, Falces C, Duchateau N, Perez-Villa F, Bijmens
465 B, Sitges M. Left atrial dysfunction relates to symptom onset in patients with
466 heart failure and preserved left ventricular ejection fraction. *European Heart*
467 *Journal - Cardiovascular Imaging* (2015) 16:62–7. doi: 10.1093/ehjci/jeu165
468 31. Stoichescu-Hogea G, Buleu FN, Christodorescu R, Sosdean R, Tudor A, Ember
469 A, Brie DM, Drăgan S. Contribution of Global and Regional Longitudinal Strain
470 for Clinical Assessment of HFpEF in Coronary and Hypertensive Patients.
471 *Medicina* (2021) 57:1372. doi: 10.3390/medicina57121372
472 32. Tanacli R, Hashemi D, Neye M, Motzkus LA, Blum M, Tahirovic E, Dordevic
473 A, Kraft R, Zamani SM, Pieske B, et al. Multilayer myocardial strain improves
474 the diagnosis of heart failure with preserved ejection fraction. *ESC Heart Failure*
475 (2020) 7:3240–5. doi: 10.1002/ehf2.12826
476 33. Wang J, Khoury DS, Yue Y, Torre-Amione G, Nagueh SF. Preserved left
477 ventricular twist and circumferential deformation, but depressed longitudinal and
radial deformation in patients with diastolic heart failure. *European Heart*

- 478 *Journal* (2008) 29:1283–9. doi: 10.1093/eurheartj/ehn141
- 479 34. Yip GW-K., Zhang Q, Xie J-M., Liang Y-J., Liu Y-M., Yan B, Lam Y-Y., Yu
- 480 C-M. Resting global and regional left ventricular contractility in patients with
- 481 heart failure and normal ejection fraction: insights from speckle-tracking
- 482 echocardiography. *Heart* (2011) 97:287–94. doi: 10.1136/hrt.2010.205815
- 483 35. Maffei C, Rossi A, Cannata L, Zocco C, Belyavskiy E, Radhakrishnan AK,
- 484 Feuerstein A, Morris DA, Pieske-Kraigher E, Pieske B, et al. Left atrial strain
- 485 predicts exercise capacity in heart failure independently of left ventricular
- 486 ejection fraction. *ESC Heart Failure* (2022) 9:842–52. doi: 10.1002/ehf2.13788
- 487 36. Michalski B, Trzeciński P, Kupczyńska K, Miśkowiec D, Pęczek Ł, Nawrot B,
- 488 Lipiec P, Kasprzak JD. The differences in the relationship between diastolic
- 489 dysfunction, selected biomarkers and collagen turn-over in heart failure patients
- 490 with preserved and reduced ejection fraction. *Cardiology Journal* (2017) 24:35–
- 491 42. doi: 10.5603/cj.a2016.0098
- 492 37. Obokata M, Takeuchi M, Negishi K, Ohte N, Izumo M, Yamashita E, Ebato M,
- 493 Yuda S, Kurabayashi M, Nakatani S. Relation Between Echocardiogram-Based
- 494 Cardiac Parameters and Outcome in Heart Failure With Preserved and Reduced
- 495 Ejection Fraction. *The American Journal of Cardiology* (2016) 118:1356–62. doi:
- 496 10.1016/j.amjcard.2016.07.060
- 497 38. Park JJ, Park J-B, Park J-H, Cho G-Y. Global Longitudinal Strain to Predict
- 498 Mortality in Patients With Acute Heart Failure. *Journal of the American College*
- 499 *of Cardiology* (2018) 71:1947–57. doi: 10.1016/j.jacc.2018.02.064
- 500 39. Tanacli R, Hashemi D, Lapinskas T, Edelmann F, Gebker R, Pedrizzetti G,
- 501 Schuster A, Nagel E, Pieske B, Dünge H-D, et al. Range Variability in CMR
- 502 Feature Tracking Multilayer Strain across Different Stages of Heart Failure.
- 503 *Scientific Reports* (2019) 9:16478. doi: 10.1038/s41598-019-52683-8
- 504 40. Xu L, Pagano J, Chow K, Oudit GY, Haykowsky MJ, Mikami Y, Howarth AG,
- 505 White JA, Howlett JG, Dyck JRB, et al. Cardiac remodelling predicts outcome in
- 506 patients with chronic heart failure. *ESC Heart Failure* (2021) 8:5352–62. doi:
- 507 10.1002/ehf2.13626
- 508 41. Gozdzik A, Marwick TH, Przewlocka-Kosmala M, Jankowska EA, Ponikowski
- 509 P, Kosmala W. Comparison of left ventricular longitudinal systolic function
- 510 parameters in the prediction of adverse outcome in heart failure with preserved
- 511 ejection fraction. *ESC Heart Failure* (2021) 8:1531–40. doi: 10.1002/ehf2.13247
- 512 42. Kalra R, Gupta K, Sheets R, Aryal S, Ebrahimi A, Rajapreyar I, Cribbs MG,
- 513 Booker OJ, Prabhu SD, Bajaj NS. Cardiac Function and Sudden Cardiac Death in
- 514 Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). *The*
- 515 *American Journal of Cardiology* (2020) 129:46–52. doi:
- 516 10.1016/j.amjcard.2020.04.038
- 517 43. Kammerlander AA, Donà C, Nitsche C, Koschutnik M, Schönbauer R, Duca
- 518 F, Zotter-Tufaro C, Binder C, Aschauer S, Beitzke D, et al. Feature Tracking of
- 519 Global Longitudinal Strain by Using Cardiovascular MRI Improves Risk
- 520 Stratification in Heart Failure with Preserved Ejection Fraction. *Radiology* (2020)
- 521 296:290–8. doi: 10.1148/radiol.2020200195
- 522 44. Romano S, Judd RM, Kim RJ, Heitner JF, Shah DJ, Shenoy C, Evans K, Romer
- 523 B, Salazar P, Farzaneh-Far A. Feature-Tracking Global Longitudinal Strain

- 524 Predicts Mortality in Patients With Preserved Ejection Fraction. *JACC:*
525 *Cardiovascular Imaging* (2020) 13:940–7. doi: 10.1016/j.jcmg.2019.10.004
- 526 45. Hwang I-C, Cho G-Y, Choi H-M, Yoon YE, Park JJ, Park J-B, Park J-H, Lee S-
527 P, Kim H-K, Kim Y-J. H2FPEF Score Reflects the Left Atrial Strain and Predicts
528 Prognosis in Patients With Heart Failure With Preserved Ejection Fraction.
529 *Journal of Cardiac Failure* (2021) 27:198–207. doi:
530 10.1016/j.cardfail.2020.09.474
- 531 46. Donal E, Lund LH, Oger E, Bosseu C, Reynaud A, Hage C, Drouet E, Daubert
532 J-Claude, Linde C. Importance of combined left atrial size and estimated
533 pulmonary pressure for clinical outcome in patients presenting with heart failure
534 with preserved ejection fraction. *European Heart Journal - Cardiovascular*
535 *Imaging* (2017) 18:629–35. doi: 10.1093/ehjci/jex005
- 536 47. Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, Schulte PJ,
537 Velazquez EJ. Left ventricular global longitudinal strain in patients with heart
538 failure with preserved ejection fraction: outcomes following an acute heart failure
539 hospitalization. *ESC Heart Failure* (2017) 4:432–9. doi: 10.1002/ehf2.12159
- 540 48. Wang J, Fang F, Wai-Kwok Yip G, Sanderson JE, Feng W, Xie J-M, Luo X-X,
541 Lee AP-W, Lam Y-Y. Left ventricular long-axis performance during exercise is
542 an important prognosticator in patients with heart failure and preserved ejection
543 fraction. *International Journal of Cardiology* (2015) 178:131–5. doi:
544 10.1016/j.ijcard.2014.10.130
- 545 49. Huang W, Chai SC, Lee SGS, MacDonald MR, Leong KTG. Prognostic Factors
546 After Index Hospitalization for Heart Failure With Preserved Ejection Fraction.
547 *The American Journal of Cardiology* (2017) 119:2017–20. doi:
548 10.1016/j.amjcard.2017.03.032
- 549 50. Freed BH, Daruwalla V, Cheng JY, Aguilar FG, Beussink L, Choi A, Klein DA,
550 Dixon D, Baldridge A, Rasmussen-Torvik LJ, et al. Prognostic Utility and
551 Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved
552 Ejection Fraction. *Circulation: Cardiovascular Imaging* (2016) 9:e003754. doi:
553 10.1161/circimaging.115.003754
- 554 51. Lejeune S, Roy C, Ciocea V, Slimani A, de Meester C, Amzulescu M, Pasquet A,
555 Vancraeynest D, Beauloye C, Vanoverschelde J-L, et al. Right Ventricular
556 Global Longitudinal Strain and Outcomes in Heart Failure with Preserved
557 Ejection Fraction. *Journal of the American Society of Echocardiography* (2020)
558 33:973-984.e2. doi: 10.1016/j.echo.2020.02.016
- 559 52. Weerts J, Barandiarán Aizpurua A, Henkens MTHM, Lyon A, van Mourik MJW,
560 van Gemert MRAA, Raafs A, Sanders-van Wijk S, Bayés-Genís A, Heymans
561 SRB, et al. The prognostic impact of mechanical atrial dysfunction and atrial
562 fibrillation in heart failure with preserved ejection fraction. *European Heart*
563 *Journal - Cardiovascular Imaging* (2021) 23:74–84. doi: 10.1093/ehjci/jeab222
- 564 53. Kosmala W, Przewlocka-Kosmala M, Rojek A, Mysiak A, Dabrowski A,
565 Marwick TH. Association of Abnormal Left Ventricular Functional Reserve
566 With Outcome in Heart Failure With Preserved Ejection Fraction. *JACC:*
567 *Cardiovascular Imaging* (2018) 11:1737–46. doi: 10.1016/j.jcmg.2017.07.028
- 568 54. Pieske B, Tschöpe C, Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu
569 M, Guazzi M, Lam CSP, et al. How to diagnose heart failure with preserved

- 570 ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus
571 recommendation from the Heart Failure Association (HFA) of the European
572 Society of Cardiology (ESC). *European Journal of Heart Failure* (2020) 22:391–
573 412. doi: 10.1002/ejhf.1741
- 574 55. Buckberg G, Hoffman JIE, Mahajan A, Saleh S, Coghlan C. Cardiac Mechanics
575 Revisited. *Circulation* (2008) 118:2571–87. doi:
576 10.1161/circulationaha.107.754424
- 577 56. Moslehi JJ, Witteles RM. Global Longitudinal Strain in Cardio-Oncology.
578 *Journal of the American College of Cardiology* (2021) 77:402–4. doi:
579 10.1016/j.jacc.2020.12.014
- 580 57. Sivapathan S, Geenty P, Deshmukh T, Boyd A, Richards D, Stewart G, Taylor
581 MS, Kwok F, Thomas L. Alterations in multi-layer strain in AL amyloidosis.
582 *Amyloid* (2022) 21:1–9. doi: 10.1080/13506129.2022.2026914
- 583 58. Steen H, Giusca S, Montenbruck M, Patel AR, Pieske B, Florian A, Erley J,
584 Kelle S, Korosoglou G. Left and right ventricular strain using fast strain-encoded
585 cardiovascular magnetic resonance for the diagnostic classification of patients
586 with chronic non-ischemic heart failure due to dilated, hypertrophic
587 cardiomyopathy or cardiac amyloidosis. *Journal of Cardiovascular Magnetic
588 Resonance* (2021) 23:45. doi: 10.1186/s12968-021-00711-w
- 589 59. Hiemstra YL, Tomsic A, van Wijngaarden SE, Palmen M, Klautz RJM, Bax JJ,
590 Delgado V, Ajmone Marsan N. Prognostic Value of Global Longitudinal Strain
591 and Etiology After Surgery for Primary Mitral Regurgitation. *JACC:
592 Cardiovascular Imaging* (2020) 13:577–85. doi: 10.1016/j.jcmg.2019.03.024
- 593 60. Shehata ML, Harouni AA, Skrok J, Basha TA, Boyce D, Lechtzin N, Mathai SC,
594 Girgis R, Osman NF, Lima JAC, et al. Regional and Global Biventricular
595 Function in Pulmonary Arterial Hypertension: A Cardiac MR Imaging Study.
596 *Radiology* (2013) 266:114–22. doi: 10.1148/radiol.12111599
- 597 61. Fan L, Namani R, Choy JS, Kassab GS, Lee LC. Transmural Distribution of
598 Coronary Perfusion and Myocardial Work Density Due to Alterations in
599 Ventricular Loading, *Geometry and Contractility*. *Frontiers in Physiology* (2021)
600 12:744855. doi: 10.3389/fphys.2021.744855
- 601 62. Xu L, Pagano JJ, Haykowsky MJ, Ezekowitz JA, Oudit GY, Mikami Y, Howarth
602 A, White JA, Dyck JRB, Anderson T, et al. Layer-specific strain in patients with
603 heart failure using cardiovascular magnetic resonance: not all layers are the same.
604 *Journal of Cardiovascular Magnetic Resonance* (2020) 22:81. doi:
605 10.1186/s12968-020-00680-6
- 606 63. Arnold JR, Kanagala P, Budgeon CA, Jerosch-Herold M, Gulsin GS, Singh A,
607 Khan JN, Chan DCS, Squire IB, Ng LL, et al. Prevalence and Prognostic
608 Significance of Microvascular Dysfunction in Heart Failure With Preserved
609 Ejection Fraction. *JACC: Cardiovascular Imaging* (2022) 5:S1936-
610 878X(21)008937. doi: 10.1016/j.jcmg.2021.11.022
- 611
612
613
614
615

616 **Tabel 1. Baseline characteristics of the 41 selected research**

617

NO	Study	Country	Sample size , n	HFpEF patients, n	Males , n	Age, mean (SD), years	Study design	LV GLS detection method	Mean or median values of LV GLS in HFpEF patients (%)	Endpoint (s)	NOS quality score
1	Ito2020	Japan	36	18	10	63	Case-control	FT-CMR	-14.8±3.3	A	8
2	Mordi2018	Uk	90	62	34	69.3	Case-control	STE	-16.0±2.2	A, C	7
3	Stoichescu-Hogea2018	Romania	102	62	53	61.5	Case-control	STE	-17.6±2.3	A, C	8
4	Carluccio2016	Italy	86	46	38	70	Case-control	STE	-15.4±3.5	A	8
5	Löffler2019	US	34	19	17	61	Case-control	FT-CMR	-17.9±3.5	A	7
6	Maffeis2022	Germany	171	86	136	65	Case-control	STE	-19.0 ± 3.0	B	6
7	Hashemi2021	Germany	49	19	35	66.9	Case-control	FT-CMR	-19.2±1.3	A, B	8
8	Bekfani2021	US	55	17	30	68.3	Case-control	STE	-18.9 ± 5.5	A, B	7
9	Blum2020	Germany	54	17	34	68.3	Case-control	FT-CMR	-19.1±1.2	A, B	8
10	Park2018	South Korea	3530	1335	1848	70.8	Case-control	STE	-15.2±4.6	B	9
11	Sanchis2015	Spain	138	63	90	75	Case-control	STE	-16.0 + 3.7	A, B	7
12	Bosch2017	Netherlands	657	219	328	66	Case-control	STE	-14.5±4.0	A, B	7
13	Bshiebish2019	Iraq	66	20	38	59	Case-control	STE	-15.0±2.0	A, B	8
14	Michalski2017	Poland	62	32	32	62.3	Case-control	STE	-16.1±6.4	B	8
15	Luo2014	China	149	45	93	61	Case-control	STE	-14.0±2.7	A, B	7
16	Fang2019	China	112	62	61	67.5	Case-control	STE	-14.5±2.6	A, C	7
17	Tanacli2020	Germany	40	20	24	70.8	Case-control	FT-CMR	-20.8±4.0	A, C	8
18	Kim2020	South Korea	96	50	42	62.8	Case-control	STE	-15.5±5.3	A, C	8
19	Kraigher-Krainer2014	Austria	269	219	140	70	Case-control	STE	-14.6 ±3.3	A	7
20	Tanacli2019	Germany	55	18	30	66.7	Case-control	FT-CMR	-12.2 ± 2.1	B	7
21	Yip2011	China	347	112	158	64.7	Case-control	STE	-15.9 ±3.9	A, B	8
22	Wang2008	US	67	20	42	52.3	Case-control	STE	-13.0 ±6.0	A, B, C	7
23	Carluccio2011	Netherlands	137	47	78	62.7	Case-control	STE	-14.4±3.3	A, B	7
24	Pellicori2014	UK	158	138	96	71.5	Case-control	STE	-13.6±3.0	A, D	6

618

619 **Continued Tabel 1. Baseline characteristics of the 41 selected research**

NO	Study	Country	Sample size , n	HFpEF patients, n	Males , n	Age, mean (SD), years	Study design	LV GLS detection method	Mean or median values of LV GLS in HFpEF patients (%)	Endpoint(s)	NOS quality score
25	Xu2021	Canada	262	97	100	69	Case-control	FT-CMR:	-18.0±3.0	B, D	8
26	Roy2020	Brussels	174	143	56	73	Case-control	STE	-16.5±3.2	A, D	7
27	Obokata2016	Japan	442	102	265	74	Case-control	STE	14.3±2.8	B, D	6
28	Gozdzik2021	Australia	201	201	53	64.8	Prospective cohort	STE	18.3±3.2	D	7
29	Kalra2020	US	1767	1767	885	72	Retrospective cohort	STE	-15.6	D	8
30	Kammerlander2020	Austria	206	206	63	71	Prospective cohort	FT-CMR	-8.2±4.5	D	8
31	Romano2020	US	1274	1274	681	57.1	Retrospective cohort	FT-CMR	-20	D	8
32	Hwang2021	South Korea	1105	1105	435	77	Prospective cohort	STE	-15.3	D	9
33	Donal2017	France	237	237	102	76	Prospective cohort	STE	-14.9±3.71	D	7
34	Buggey2017	US	739	739	177	69	Prospective cohort	STE	-13.4±3.8	D	8
35	Wang2015	China	80	80	50	66	Prospective cohort	STE	-18.15±3.3	D	8
36	Huang2017	Singapore	129	129	67	75.1	Prospective cohort	STE	-13.5±4.0	D	7
37	Shah2015	US	447	447	207	70.3	Prospective cohort	STE	-15.6±3.5	D	9
38	Freed2016	Chicago	308	308	111	65	Prospective cohort	STE	-17.5±4.1	D	8
39	Lejeune2020	Belgium	149	149	58	78	Prospective cohort	STE	-16.7±3.1	D	7
40	Weerts2021	Spain	258	258	79	75.6	Prospective cohort	STE	-17.7±4.4	D	6
41	Kosmala2018	Australia	205	205	55	64.8	Prospective cohort	STE	-18.2±3.4	D	8

620 **Abbreviations:** HFpEF: Heart (HF) with preserved ejection fraction; STE: speckle-tracking echocardiography; FT-CMR: feature-tracking cardiovascular magnetic
621 resonance

622 **Endpoint (s) :** A: Differences in LV GLS Values between HFpEF Patients and Healthy Controls; B: Differences in LV GLS Values between HFpEF Patients and HFrEF
623 Patients; C: Diagnostic Value of LV GLS Values in HFpEF; D: Prognostic Value of LV GLS Values in HFpEF Patients

624

625

626

627 **Table 2. Data related to diagnostic meta-analysis**

	Study	LVGLS cut-off (%)	AUC	SEN (%)	SPE(%)	TP	FP	FN	TN	P-value
1	Mordi2018	-17.8	0.78	0.83	0.63	52	10	11	17	0.037
2	Stoichescu-Hogea2018	-19.35	0.83	0.79	0.47	49	21	13	19	<0.001
3	Fang2019	—	0.87	—	—	—	—	—	—	<0.001
4	Tanacli2020	-24.1	0.69	0.90	0.41	18	12	2	8	0.037
5	Kim2020	-16.7	0.68	0.54	0.85	27	7	23	39	0.001
6	Wang2008	-16	0.98	0.95	0.95	19	1	1	16	<0.001

628 **Abbreviations:** LV GLS: left ventricular global longitudinal strain **TP:** True positive; **FP:** False positive; **FN:** False negative; **TN:** True negative; **SEN:** Sensitivity;
629 **SPE:** Specificity.

630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646

647 **Table 3. Data related to Meta-analysis of prognostic assessment**

NO	Study	Variables adjusted	Follow-up Duration (months)	Endpoint(s)	Hazard ratios	95% CIs	P-value
1	Pellicori2014	–	21.6	CV death and HF hospitalization	1.09	1.00–1.19	0.046
2	Xu2021	–	90	All-cause death and CV hospitalization	1.00	0.98-1.02	0.93
3	Roy2020	–	30	All cause death	1.04	0.94-1.15	
4	Obokata2016	–	11.4	All-cause death and HF hospitalization	1.00	0.93-1.07	0.95
5	Goździk2021	–	48	CV death and HF hospitalization	0.99	0.87-1.13	0.92
6	Kalra2020	MAGGIC Risk Score, BNP, and peak VO2	34.8	CV death and HF hospitalization	0.91	0.84-0.98	0.016
7	Kammerlander2020	Age, sex, race, medical history (stroke, heart rate, and AF), NYHA class, randomization strata, randomized treatment assignment, hematocrit, and creatinine.	39	All-cause death	1.58	1.12-2.22	0.009
8	Romano2020	Age, sex, NT-pro BNP, LA volume, RV end-diastolic volume, and RV ejection fraction	74.4	CV death and HF hospitalization	1.06	1.01- 1.11	0.03
9	Hwang2021	Age, BMI, medical history (diabetes, hypertension), heart rate, diastolic blood pressure, LV end diastolic volume index, LV ejection fraction, LA volume, and RV ejection fraction	30	All case death	1.21	1.157–1.270	<0.001
10	Donal2017	–	18	All-cause death and HF hospitalization	1.40	1.176–1.667	<0.001
11	Buggey2017	Age, sex, medical history (arterial hypertension, AF, and renal insufficiency) , and hemoglobin.	12	All-cause death and HF hospitalization	1.94	1.22 3.07	0.0047
12	Wang2015	Age, sex, medical history (renal insufficiency, diabetes, hypertension, lung disease), systolic blood pressure, NT-pro BNP, RV systolic pressure, moderate mitral stenosis, moderate aortic stenosis, and E/e' ratio.	36	All case death	1.02	0.96–1.08	0.562
13	Huang2017	Age, sex, medical history (hypertension, diabetes mellitus, and anemia), history of cardiac-related medications, the body surface area, NYHA class	37.5	All-cause death and HF hospitalization	1.03	0.98–1.08	0.204
14	Shah2015	Sex, race, BMI, echocardiography data, NT-pro BNP, and Troponin T.	34.8	All-cause death and HF hospitalization	0.79	0.67–0.91	0.008
		Age, sex, race, medical history (AF, stroke), heart rate, NYHA class, creatinine, echocardiography data (LVEF, LV mass, E/e' ratio.), randomization strata, region of enrollment, randomized treatment assignment		All-cause death	4.72	1.25-17.81	0.022
				CV death and HF hospitalization	2.14	1.26-3.66	0.005

648

649 **Continued Tabel 3. Data related to Meta-analysis of prognostic assessment**

NO	Study	Variables adjusted	Follow-up Duration (months)	Endpoint(s)	Hazard ratios	95% CIs	P-value
15	Freed2016	Sex, AF, MAGGIC Risk Score, LV mass, LA volume, E/e' ratio	13.8	All-cause death and CV hospitalization	1.17	0.95–1.43	0.13
16	Lejeune2020	–	30	All-cause death and HF hospitalization	1.066	0.964–1.178	0.22
17	Weerts2021	–	36	All-cause death and HF hospitalization	1.019	0.951–1.093	0.59
18	Kosmala2018	–	26.2	HF Hospitalization	0.958	0.909–1.010	0.115
				All-cause death and CV hospitalization	1.76	0.23–13.52	0.584
					2.12	0.35–12.74	0.411

650 **Abbreviations: MAGGIC Risk Score:** age, ejection fraction, creatinine, diabetes, chronic obstructive pulmonary disease, systolic blood pressure, body-mass index, heart
651 rate, New York Heart Association functional class, ACE-inhibitor use, beta-blocker use, heart failure duration, and current smoker; **AF:** atrial fibrillation; **NYHA:** New
652 York Heart Association; **LA:** left atrial volume; **RV:** right ventricular; **LV:** left ventricular; **BMI:** body-mass index; **LVEF:** LV ejection fraction.

653

654

655

656

657

658

659

660

661

662 **Figure Legends**

663 **Fig.1** Flowchart of Database Search and Text Screening Procedure

664 **Fig.2** Differences in LV GLS Values between HFpEF Patients and Control Groups

665 (A) Mean LV GLS Values in HFpEF Patients and Healthy Controls

666 (B) Mean LV GLS Values in HFpEF Patients and HFrEF Patients

667 (C) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to Healthy Controls

668 (D) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to HFrEF Patients

669 **Fig.3** Diagnostic Value of LVGLS in Patients with HFpEF

670 (A) Sensitivity

671 (B) Specificity

672 (C) Positive Likelihood Ratio

673 (D) Negative Likelihood Ratio

674 (E) Diagnostic Odds Ratio

675 (F) SROC

676 **Fig.4** Associations between Low LV GLS Values and Adverse Outcomes in HFpEF Patients

677 (A) Forest Plot of the Association between Low LV GLS Values and All-cause Death in
678 HFpEF Patients

679 (B) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome
680 of All-cause Death and HF Hospitalization in HFpEF Patients

681 (C) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome
682 of CV Death and HF Hospitalization in HFpEF Patients






Fig.1 Flowchart of Database Search and Text Screening Procedure

(A) Mean LV GLS Values in HFpEF Patients and Healthy Controls (B) Mean LV GLS Values in HFpEF Patients and HFrEF Patients



(C) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to Healthy Controls



(D) Forest Plot of mean LV GLS Values in HFpEF Patients Compared to HFrEF Patients





Fig.2 Differences in LV GLS Values between HFpEF Patients and


(A) Sensitivity



Study	Sensitivity (95% CI)
Mordi2018	0.83 (0.71 - 0.91)
Stoichescu-Hogea2018	0.88 (0.81 - 0.95)
Tanacli2020	0.85 (0.78 - 0.92)
Kim2020	0.54 (0.39 - 0.68)
Wang2008	0.95 (0.75 - 1.00)

Pooled Sensitivity = 0.77 (0.71 to 0.82)
Chi-square = 21.24; df = 4 (p = 0.0003)
Inconsistency (I-square) = 81.2 %


(B) Specificity



Study	Specificity (95% CI)
Mordi2018	0.63 (0.42 - 0.81)
Stoichescu-Hogea2018	0.47 (0.32 - 0.64)
Tanacli2020	0.41 (0.19 - 0.64)
Kim2020	0.85 (0.71 - 0.94)
Wang2008	0.95 (0.71 - 1.00)

Pooled Specificity = 0.66 (0.58 to 0.74)
Chi-square = 27.60; df = 4 (p = 0.0000)
Inconsistency (I-square) = 85.5 %


(C) Positive Likelihood Ratio



Study	Positive LR (95% CI)
Mordi2018	2.23 (1.35 - 3.69)
Stoichescu-Hogea2018	1.51 (1.09 - 2.08)
Tanacli2020	1.50 (1.02 - 2.21)
Kim2020	3.55 (1.71 - 7.35)
Wang2008	16.15 (2.41 - 108.42)

Random Effects Model
Pooled Positive LR = 2.17 (1.36 to 3.47)
Cochran-Q = 14.77; df = 4 (p = 0.0052)
Inconsistency (I-square) = 72.9 %
Tau-squared = 0.1815


(D) Negative Likelihood Ratio



Study	Negative LR (95% CI)
Mordi2018	0.28 (0.15 - 0.51)
Stoichescu-Hogea2018	0.44 (0.25 - 0.79)
Tanacli2020	0.25 (0.06 - 1.03)
Kim2020	0.54 (0.39 - 0.75)
Wang2008	0.05 (0.01 - 0.36)

Random Effects Model
Pooled Negative LR = 0.35 (0.21 to 0.59)
Cochran-Q = 10.80; df = 4 (p = 0.0289)
Inconsistency (I-square) = 63.0 %
Tau-squared = 0.1922

(E) Diagnostic Odds Ratio



Study	Diagnostic OR(95% CI)
Mordi2018	8.04 (2.91 - 22.21)
Stoichescu-Hogea2018	3.41 (1.43 - 8.15)
Tanacli2020	6.00 (1.08 - 33.27)
Kim2020	6.54 (2.46 - 17.39)
Wang2008	304.00 (17.58 - 5,258.01)

Random Effects Model


Pooled Diagnostic Odds Ratio = 7.53 (3.19 to 17.74)

Cochran-Q=9.34;df=4(p=0.0531)

Inconsistency(I-square)=57.2%

Tau-squared=0.5023


(F) SROC




Symmetric SROC
AUC=0.81 (0.79-0.87)
SE(AUC)=0.0588
Q=0.7488
SE(Q)=0.0524

Fig.3 Diagnostic Value of LVGLS in Patients with HFpEF

(A) Forest Plot of the Association between Low LV GLS Values and All-cause Death in HFpEF Patients



(B) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome of All-cause Death and HF Hospitalization in HFpEF Patients



(C) Forest Plot of the Association between Low LV GLS Values and the Composite Outcome of CV Death and HF Hospitalization in HFpEF Patients




Fig.4 Associations between Low LV GLS Values and Adverse Outcomes